Clinical Trial Update: Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study comparing anastrozole plus gefitinib to fulvestrant plus gefitinib in postmenopausal women with metastatic breast cancer; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• Faslodex (fulvestrant)
• Iressa (gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-05-06